Inventor
ZION TODD C
US50 patents
⚠️ This page may combine multiple inventors who share the name “ZION TODD C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AKSTON BIOSCIENCES CORP
22 patentsUS10961294B2Mar 30, 2021
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP24 citations94
US10947292B2Mar 16, 2021
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP23 citations94
US10870686B2Dec 22, 2020
Ultra-long acting insulin-FC fusion proteins and methods of use
AKSTON BIOSCIENCES CORP23 citations94
US10851147B2Dec 1, 2020
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP23 citations94
US10597435B2Mar 24, 2020
Insulin-Fc fusions and methods of use
AKSTON BIOSCIENCES CORP21 citations92
US11261229B2Mar 1, 2022
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP3 citations84
US11192930B2Dec 7, 2021
Ultra-long acting insulin-Fc fusion protein and methods of use
AKSTON BIOSCIENCES CORP5 citations84
US11186623B2Nov 30, 2021
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP6 citations84
US11359001B2Jun 14, 2022
Insulin-Fc fusions and methods of use
AKSTON BIOSCIENCES CORP7 citations83
US11919935B2Mar 5, 2024
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP2 citations73
US11814418B2Nov 14, 2023
Ultra-long acting insulin-Fc fusion protein and methods of use
AKSTON BIOSCIENCES CORP2 citations73
US11773151B2Oct 3, 2023
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP2 citations73
US11673934B2Jun 13, 2023
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP2 citations73
US11267862B2Mar 8, 2022
Ultra-long acting insulin-Fc fusion proteins and methods of use
AKSTON BIOSCIENCES CORP3 citations73
US11198719B2Dec 14, 2021
Ultra-long acting insulin-Fc fusion protein and methods of use
AKSTON BIOSCIENCES CORP2 citations73
US11213581B2Jan 4, 2022
Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
AKSTON BIOSCIENCES CORP3 citations71
US12454565B2Oct 28, 2025
PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use
AKSTON BIOSCIENCES CORP1 citations64
US12195511B2Jan 14, 2025
Ultra-long acting insulin-Fc fusion protein
AKSTON BIOSCIENCES CORP0 citations62
US11555058B2Jan 17, 2023
Cells engineered to express ultra-long acting insulin-Fc fusion proteins
AKSTON BIOSCIENCES CORP0 citations62
US11352407B2Jun 7, 2022
Ultra-long acting insulin-Fc fusion proteins
AKSTON BIOSCIENCES CORP1 citations62
US11707517B2Jul 25, 2023
Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
AKSTON BIOSCIENCES CORP0 citations60
US11667689B2Jun 6, 2023
Insulin-Fc fusion proteins and methods of use to treat cancer
AKSTON BIOSCIENCES CORP0 citations52
SMARTCELLS INC
8 patentsUS7687608B2Mar 30, 2010
Methods for reducing the mitogenicity of lectin compositions
SMARTCELLS INC21 citations89
US10398781B2Sep 3, 2019
Conjugate based systems for controlled drug delivery
SMARTCELLS INC1 citations73
US9579391B2Feb 28, 2017
Conjugate based systems for controlled drug delivery
SMARTCELLS INC2 citations73
US9463249B2Oct 11, 2016
Crystalline insulin-conjugates
SMARTCELLS INC5 citations73
US9114176B2Aug 25, 2015
Exogenously triggered controlled release materials and uses thereof
SMARTCELLS INC4 citations73
US9265838B2Feb 23, 2016
Conjugate based systems for controlled drug delivery
SMARTCELLS INC2 citations62
US9745355B2Aug 29, 2017
Binding-site modified lectins and uses thereof
SMARTCELLS INC0 citations41
US9095623B2Aug 4, 2015
Terminally-functionalized conjugates and uses thereof
SMARTCELLS INC0 citations41
ZION TODD C
7 patentsUS9050370B2Jun 9, 2015
Conjugate based systems for controlled drug delivery
ZION TODD C9 citations84
US8906850B2Dec 9, 2014
Crystalline insulin-conjugates
ZION TODD C12 citations84
US8846103B2Sep 30, 2014
Exogenously triggered controlled release materials and uses thereof
ZION TODD C7 citations84
US8569231B2Oct 29, 2013
Soluble non-depot insulin conjugates and uses thereof
ZION TODD C7 citations84
US8940690B2Jan 27, 2015
Synthetic conjugates and uses thereof
ZION TODD C6 citations73
US8623345B2Jan 7, 2014
Terminally-functionalized conjugates and uses thereof
ZION TODD C4 citations73
US8603529B2Dec 10, 2013
Polynucleotide aptamer-based cross-linked materials and uses thereof
ZION TODD C5 citations73
LANCASTER THOMAS M
4 patentsUS9074015B2Jul 7, 2015
Recombinantly expressed insulin polypeptides and uses thereof
LANCASTER THOMAS M23 citations87
US9068013B2Jun 30, 2015
Recombinant lectins, binding-site modified lectins and uses thereof
LANCASTER THOMAS M7 citations75
US8729242B2May 20, 2014
Methods for reducing the mitogenicity of lectin compositions
LANCASTER THOMAS M1 citations58
US8697643B2Apr 15, 2014
Method for controllably releasing a drug conjugate within subcutaneous tissue in response to the local concentration of an indicator
LANCASTER THOMAS M1 citations55